Substance / Medication

Eletriptan hydrobromide

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.
Kim Yu Kyong, Shin Kwang-Hee, Alderman Jeffrey et al. · Drug Des Devel Ther · 2018
PMID: 29497279RCTFull text (PMC)
Study of forced degradation behavior of eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method.
Jocić Biljana, Zecević Mira, Zivanović Ljiljana et al. · J Pharm Biomed Anal · 2009
PMID: 19250786Observational
Novel Application of UHPLC-MS, HRMS, and 2D-NMR for Structural Elucidation of Eletriptan Hydrobromide and Its Novel Degradation Products.
Bhuma Dastagiri Reddy, Maddala Venkata Kanaka Srivani, Salakolasu Suresh et al. · Biomed Chromatogr · 2026
PMID: 41507031OtherFull text (PMC)
Statistically Optimized Polymeric Buccal Films of Eletriptan Hydrobromide and Itopride Hydrochloride: An In Vivo Pharmacokinetic Study.
Safhi Awaji Y, Siddique Waqar, Zaman Muhammad et al. · Pharmaceuticals (Basel) · 2023
PMID: 38004417OtherFull text (PMC)
Development of assay for determination of eletriptan hydrobromide in loaded PLGA nanoparticles.
Esim Ozgur, Savaser Ayhan, Kurbanoglu Sevinc et al. · J Pharm Biomed Anal · 2017
PMID: 28499152Other
Synthesis of compounds related to the anti-migraine drug eletriptan hydrobromide.
Madasu Suri Babu, Vekariya Nagaji Ambabhai, Kiran M N V D Hari et al. · Beilstein J Org Chem · 2012
PMID: 23019477OtherFull text (PMC)
Thermoreversible nanoethosomal gel for the intranasal delivery of Eletriptan hydrobromide.
Shelke Santosh, Shahi Sadhana, Jadhav Kiran et al. · J Mater Sci Mater Med · 2016
PMID: 27091045Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eletriptan hydrobromide (substance)
SNOMED CT
425436002
UMLS CUI
C1178489

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.